Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-627 in breast cancer patients receiving chemotherapy
NCT02527746Phase 1Completed
- Sponsor
- Evive Biotech
- Start
- Dec 2012
- Primary completion
- Dec 2013
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 1, open-label trial of efbemalenograstim alfa in neutropenia (3 arms), sponsored by Evive Biotech. Primary endpoints: Evaluate the Safety of F-627 for Injection and Tolerability (Dose-limiting Toxicity) of F-627 up to 21 days. Started Dec 2012; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02527746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527746.